Allakos (ALLK) Competitors $0.29 0.00 (-1.62%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.28 0.00 (-0.70%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALLK vs. DERM, TCRX, ARTV, PROC, RANI, ATOS, CRBP, CLYM, ZURA, and ANIXShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Journey Medical (DERM), TScan Therapeutics (TCRX), Artiva Biotherapeutics (ARTV), Procaps Group (PROC), Rani Therapeutics (RANI), Atossa Therapeutics (ATOS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zura Bio (ZURA), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Journey Medical TScan Therapeutics Artiva Biotherapeutics Procaps Group Rani Therapeutics Atossa Therapeutics Corbus Pharmaceuticals Climb Bio Zura Bio Anixa Biosciences Allakos (NASDAQ:ALLK) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership. Does the MarketBeat Community believe in ALLK or DERM? Allakos received 178 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformAllakosOutperform Votes18358.84% Underperform Votes12841.16% Journey MedicalOutperform Votes5100.00% Underperform VotesNo Votes Is ALLK or DERM more profitable? Allakos has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. Journey Medical's return on equity of -132.10% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets AllakosN/A -140.87% -86.22% Journey Medical -31.74%-132.10%-26.90% Do analysts recommend ALLK or DERM? Allakos currently has a consensus target price of $2.00, indicating a potential upside of 599.30%. Journey Medical has a consensus target price of $9.67, indicating a potential upside of 86.26%. Given Allakos' higher probable upside, equities research analysts clearly believe Allakos is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Journey Medical 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media refer more to ALLK or DERM? In the previous week, Journey Medical had 2 more articles in the media than Allakos. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for Allakos. Journey Medical's average media sentiment score of 0.97 beat Allakos' score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media. Company Overall Sentiment Allakos Neutral Journey Medical Positive Do insiders and institutionals have more ownership in ALLK or DERM? 84.6% of Allakos shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 16.1% of Allakos shares are held by company insiders. Comparatively, 13.2% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ALLK or DERM? Allakos has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Which has stronger valuation and earnings, ALLK or DERM? Journey Medical has higher revenue and earnings than Allakos. Journey Medical is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllakosN/AN/A-$185.70M-$2.03-0.14Journey Medical$79.18M1.37-$3.85M-$0.94-5.52 SummaryJourney Medical beats Allakos on 12 of the 18 factors compared between the two stocks. Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.55M$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.146.1326.4618.82Price / SalesN/A311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book0.156.747.634.64Net Income-$185.70M$138.11M$3.18B$245.69M7 Day Performance-8.54%-2.43%-1.91%-2.66%1 Month Performance-74.46%-1.91%-0.19%-2.15%1 Year Performance-78.66%-5.03%16.70%12.90% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.2278 of 5 stars$0.29-1.6%$2.00+599.3%-77.8%$25.55MN/A-0.14190DERMJourney Medical2.5229 of 5 stars$5.24+1.0%$9.67+84.5%+38.0%$109.46M$79.18M-5.5790TCRXTScan Therapeutics2.4626 of 5 stars$2.05+0.5%$11.25+448.8%-68.8%$109.41M$9.36M-1.93100ARTVArtiva BiotherapeuticsN/A$4.44+10.7%$21.00+373.0%N/A$107.85MN/A0.0081News CoveragePROCProcaps GroupN/A$0.95-40.3%N/A-73.4%$107.18M$409.92M0.004,900News CoverageGap DownHigh Trading VolumeRANIRani Therapeutics3.5936 of 5 stars$1.85+0.5%$12.33+566.7%-49.2%$105.99MN/A-1.75110ATOSAtossa Therapeutics1.3108 of 5 stars$0.83+1.9%$7.00+743.2%-21.3%$104.44MN/A-3.778Positive NewsCRBPCorbus Pharmaceuticals4.0441 of 5 stars$8.51-10.2%$61.38+621.2%-69.9%$103.65MN/A-1.8140Analyst ForecastHigh Trading VolumeCLYMClimb Bio2.4906 of 5 stars$1.52-4.4%$10.00+557.9%N/A$102.17MN/A-0.719Gap UpZURAZura Bio2.8476 of 5 stars$1.55+3.3%$15.80+919.4%-62.0%$101.20MN/A0.003Gap UpANIXAnixa Biosciences2.9765 of 5 stars$3.14-0.3%$8.50+170.7%-18.3%$101.11M$210,000.00-8.055Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Journey Medical Competitors TScan Therapeutics Competitors Artiva Biotherapeutics Competitors Procaps Group Competitors Rani Therapeutics Competitors Atossa Therapeutics Competitors Corbus Pharmaceuticals Competitors Climb Bio Competitors Zura Bio Competitors Anixa Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALLK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLK Stock Alerts